| | 
Part, Chapter, Paragraph
1 II, 4. 3 | Robine, J.-M. and J.-P. Michel (2004): Looking
2 II, 5. 2. 6 | Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash
3 II, 5. 2. 7 | Allender S, Scarborough P, Peto V and Rayner M (2008):
4 II, 5. 2. 7 | LL, Garside DB, Greenland P, Manheim LM, Dyer AR, Wang
5 II, 5. 2. 7 | J 28: 2375-414~Greenland P, Knoll MD, Stamler J,. Neaton
6 II, 5. 2. 7 | G, Ferrario M, Chiodini P, Sega R, and Stamler J (
7 II, 5. 2. 7 | Donfrancesco C, Vanuzzo D, Chiodini P, Cesana G, Ferrario M, Mattiello
8 II, 5. 2. 7 | Cardiovasc Dis 18: S1-16.~Puska P, Vartiainen E, Tuomilehto
9 II, 5. 2. 7 | H, Ruokokoski E, Amouyel P (1999): Contribution of
10 II, 5. 2. 7 | McQueen M, Budaj A, Pais P, Varigo J, Lisheng A (2004):
11 II, 5. 3. 9 | Oncology 8 (9):773-783.~ ~Boyle P, Autier P, Bartelink H,
12 II, 5. 3. 9 | 773-783.~ ~Boyle P, Autier P, Bartelink H, et al (2003):
13 II, 5. 3. 9 | 2008).~ ~Ferlay J, Autier P, Boniol M, Heanue M, Colombet
14 II, 5. 3. 9 | Heanue M, Colombet M, Boyle P (2007): Estimates of the
15 II, 5. 3. 9 | Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M,
16 II, 5. 3. 9 | Issues.~ ~Key T, Appleby P, Barnes I, Reeves G, Endogenous
17 II, 5. 3. 9 | iii7.~ ~Micheli A, Baili P, Quinn M, Mugno E, Capocaccia
18 II, 5. 3. 9 | Capocaccia R, Grosclaude P, and the EUROCARE Working
19 II, 5. 3. 9 | Mugno E, Coebergh JW, Baili P, Verdecchia A, Berrino F,
20 II, 5. 3. 9 | Bray F, Ferlay J, Pisani P (2005): Global cancer statistics,
21 II, 5. 3. 9 | Bielska Lasota M, Carli P, Faivre J, Grosclaude P,
22 II, 5. 3. 9 | P, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Moller
23 II, 5. 3. 9 | Santaquilani M, Roazzi P, Lisi D, EUROCARE Working
24 II, 5. 3. 9 | Stewart BW, Kleihues P (2003): World Cancer Report.
25 II, 5. 4. 8 | 1995 Mar;12(3):271-6~Beck, P, Battlogg, K, Gfrerer, R,
26 II, 5. 4. 8 | R, Trajanoski, Z, Wach, P, and Pieber, T. (2001) Internet
27 II, 5. 4. 8 | Kristensen JK, Ottosen P, Borch-Johnsen K (2008);
28 II, 5. 5.Int(9) | Gabriel P and Liimatainen M-R (2000):
29 II, 5. 5.Int(11)| Sen. G., A. George, and P. Östlin (eds.) Engendering
30 II, 5. 5.Int(12)| differences in mental health. In P. Östlin, M. Danielsson,
31 II, 5. 5.Int(15)| AW, Dewey ME, Delespaul P, Fuhrer R, Hooijer C, Lawlor
32 II, 5. 5. 1 | change estimated at -6.1%(P<0.0001), –5.4%(P<0.0001)
33 II, 5. 5. 1 | at -6.1%(P<0.0001), –5.4%(P<0.0001) and –5.0%(P<0.0001)
34 II, 5. 5. 1 | 5.4%(P<0.0001) and –5.0%(P<0.0001) respectively.~ ~
35 II, 5. 5. 3 | Dallongeville J, Gilbert CC, Bergman P, Widhalm K, Manios Y, Breidenasse
36 II, 5. 5. 3 | 12:18-23.~Andlin-Sobocki P, Jönsson B, Wittchen HU,
37 II, 5. 5. 3 | Suppl 1:1-27.~Andlin-Sobocki P, Rössler W (2002):Health
38 II, 5. 5. 3 | 7):155-8.~Andlin-Sobocki P, & Rössler W (2005):Cost
39 II, 5. 5. 3 | Baumann A, Zäske H, Decker P, Klosterkötter J, Maier
40 II, 5. 5. 3 | de Girolamo G, Morosini P, Polidori G, Kikkawa T,
41 II, 5. 5. 3 | Jané-Llopis E, Anderson P eds.).~Fang H, Rizzo JA (
42 II, 5. 5. 3 | Klosterkötter J, Maier W, Decker P, Möller HJ. (2007): Evaluation
43 II, 5. 5. 3 | Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards
44 II, 5. 5. 3 | Lange W, Munk-Jørgensen P, Bertelsen A, Schürmann
45 II, 5. 5. 3 | Lysaker PH, Tsai J, Yanos P, Roe D (2007): Associations
46 II, 5. 5. 3 | 53.~Pilling S, Bebbington P, Kuipers E, Garety P, Geddes
47 II, 5. 5. 3 | Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan
48 II, 5. 5. 3 | Wahlbeck K), Section B, p. 257-333, 2007.~htt df~Vauth
49 II, 5. 5. 3 | Questionnaire and GP and P inquiry/MR review? ~155/
50 II, 5. 5. 3 | years MR = Medical record P = Pediatricians ~ = 6-16
51 II, 5. 5. 3 | epilepsy and 75% in controls (p<0.0001). The cumulative
52 II, 5. 5. 3 | 27 and 17% respectively (p<0.0001). Illnesses and accidents
53 II, 5. 5. 3 | Oxford, Blackwell Science; p. 50-63.~Beghi E, Sander
54 II, 5. 5. 3 | Oxford, Blackwell Science; p. 21-42.~Forsgren L, Beghi
55 II, 5. 5. 3 | Gallitto G, Serra S, La Spina P, et al (2005): Prevalence
56 II, 5. 5. 3 | Epilepsia 45:1405-1415.~Jallon P (2004): Mortality in patients
57 II, 5. 5. 3 | 1030.~Loiseau J, Loiseau P, Guyot M, et al (1990):
58 II, 5. 5. 3 | Loiseau J, Picot MC, Loiseau P (1999): Short-term mortality
59 II, 5. 5. 3 | Nashef L, Walker F, Allen P, et al (1996): Apnoea and
60 II, 5. 5. 3 | Olafsson E, Ludvigsson P, Gudmundsson G, et al (2005):
61 II, 5. 5. 3 | 37:1051-1059.~Pazzaglia P, Frank-Pazzaglia L (1976):
62 II, 5. 5. 3 | 1790-1791.~Rutter M, Graham P, Yule W (1970): A neuropsychiatric
63 II, 5. 5. 3 | Boca Raton, FL: CRC Press; p. 239-148.~Tomson T, Beghi
64 II, 5. 5. 3 | Kesselring J, Ketelaer P, Thompson A et al; (2004):
65 II, 5. 5. 3 | Confavreux C, Vukusic S, Adeleine P (2003): Early clinical predictors
66 II, 5. 5. 3 | Darmstadt.~Flachenecker P, Zettl UK , Götze U, et
67 II, 5. 5. 3 | in German]~Flachenecker P, Zettl UK, Elias WG, et
68 II, 5. 5. 3 | 294.~Henze T, Rieckman, P and Toyka KY (2006): Symptomatic
69 II, 5. 5. 3 | Hungarica 13:47-48.~Jedlicka P (1989): Epidemiology of
70 II, 5. 5. 3 | Leuchtturm-Verlag/LTV Press, Darmstadt, p 294.~Krupp LB, Alvarez LA,
71 II, 5. 5. 3 | 1985;38(2):203-10.~Lensky P (1994): Geographic disproportion
72 II, 5. 5. 3 | consensus group) and Rieckmann P (2006): Escalating immunomodulatory
73 II, 5. 5. 3 | Amsterdam.~Ranzato F, Perini P, Tzintzeva E et al (2003):
74 II, 5. 5. 3 | Scand 110: 331–336.~Sobocki P, Pugliatti M, Lauer L, Kobelt
75 II, 5. 5. 3 | Psychiatry 74:25-28.~Sundström P, Nyström L, Forsgren L (
76 II, 5. 5. 3 | Scand 103:214-218.~Sundström P, Nyström L, Forsgren L (
77 II, 5. 5. 3 | Psychiatry 74:29-32.~Sundström P, Svenningsson A, Nyström
78 II, 5. 5. 3 | at http f]~Van Ooteghem P, De Hooghe MB, Vlietnick
79 II, 5. 5. 3 | 1):21-27.~Andlin-Sobocki P, Jonsson B, Wittchen HU,
80 II, 5. 5. 3 | Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E,
81 II, 5. 5. 3 | Monetti VC, De Bastiani P (1991): Parkinson’s disease
82 II, 5. 5. 3 | G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel
83 II, 5. 5. 3 | Pharmacoeconomics 16(1):59-69.~Lindgren P, von Campenhausen S, Spottke
84 II, 5. 5. 3 | 113(9):1234-1238.~McCrone P, Allcock LM, Burn DJ (2007):
85 II, 5. 5. 3 | W, Reichmann H, Riederer P, Trenkwalder C, Dodel R,
86 II, 5. 5. 3 | Aiello I, Tola R, De Bastiani P, Pirisi A, Devoto MC (1980):
87 II, 5. 6. 6 | 13~Bergman S, Herrstrom P, Hogstrom K, Petersson IF,
88 II, 5. 6. 6 | Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM,
89 II, 5. 6. 6 | Metab 314:224-229~Croft P, Coggon D, Cruddas M, Cooper
90 II, 5. 6. 6 | 1709~Hakala M, Nieminen P, Koivisto O (1994): More
91 II, 5. 6. 6 | Care 16(4):1193-200~Juni P, Dieppe P, Donovan J, Peters
92 II, 5. 6. 6 | 1193-200~Juni P, Dieppe P, Donovan J, Peters T, Eachus
93 II, 5. 6. 6 | Karaharju EO, Porras M, Luthje P, Jakobsson A (1988): Functional
94 II, 5. 6. 6 | Marples G, Chandler C, Dawson P (1999): Prevalence of back,
95 II, 5. 6. 6 | Dreinhofer K, Schrader P, Sturmer T, Puhl W, Gunther
96 II, 5. 6. 6 | adults.~Oleksik A, Lips P, Dawson A, Minshall ME,
97 II, 5. 6. 6 | E, Torrance GW, Tugwell P (1992): Physical disability
98 II, 5. 6. 6 | Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott
99 II, 5. 7. 7 | Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK,
100 II, 5. 7. 7 | 441-8.~Otero A, Gayoso P, Garcia F, de Francisco
101 II, 5. 7. 7 | S16-S19.~Pontoriero G, Pozzoni P, Vecchio LD, Locatelli F (
102 II, 5. 8. 3 | glaucoma (RR = 1.3) [all p <0.05].~ ~The Longitudinal
103 II, 5. 8. 5 | spirometric parameters (p<0.001). In the second part,
104 II, 5. 8. 6 | setting (41% vs. 12.5%, p<0.05) and to receive long-term
105 II, 5. 8. 6 | home care (26% vs 9.7%, p<0.05), but were much less
106 II, 5. 8. 6 | hospital (47.6% vs 5.1%, p<0.001) or at home (37.4%
107 II, 5. 8. 6 | at home (37.4% vs 2.8%, p<0.05) than people with lung
108 II, 5. 8. 7 | Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K,
109 II, 5. 8. 7 | M, Blanc P, Henneberger P, Kreiss K, Mapp C, Milton
110 II, 5. 8. 7 | Baekke Borgeskov H, Lange P (2007): The cost of treating
111 II, 5. 8. 7 | WM, Gillespie S, Burney P, Mannino DM, Menezes AMN,
112 II, 5. 8. 7 | C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney
113 II, 5. 8. 7 | Svanes C, Anto JM, Burney P (2004): European Community
114 II, 5. 8. 7 | Huchon G, Huas D, Godard P, Voinet C, Chanal I, Jourdanne
115 II, 5. 8. 7 | Nieminen MM, Aine T, Bakke P, Janson C (2007): Mortality
116 II, 5. 8. 7 | Johannessen A, Omenaas E, Bakke P, Gulsvik A (2005): Incidence
117 II, 5. 8. 7 | Jorgensen NR, Schwarz P, Holme I, Henriksen BM,
118 II, 5. 8. 7 | 879-885.~ ~Lokke A, Lange P, Scharling H, Fabricius
119 II, 5. 8. 7 | Scharling H, Fabricius P, Vestbo J (2006): Developing
120 II, 5. 8. 7 | Stewart A, Lamont C, Roseman P, Didsbury P (2004): A chronic
121 II, 5. 8. 7 | Lamont C, Roseman P, Didsbury P (2004): A chronic disease
122 II, 5. 8. 7 | Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes
123 II, 5. 8. 7 | Stratelis G, Jakobsson P, Molstad S, Zetterstrom
124 II, 5. 8. 7 | Kogevinas M, Kromhout H, Burney P, Antó Jm, and The ECRHS
125 II, 5. 9. 3 | women and 49.5% in men, P 001). Asthmatic patients
126 II, 5. 9. 3 | onset (7.8 vs 15.9 years, P 001) and a shorter duration
127 II, 5. 9. 3 | disease (5.6 vs 16.1 years, P 001) than patients with
128 II, 5. 9. 3 | remission was strongly (P 001) and inversely related
129 II, 5. 9. 3 | significant correlation (P<0.0001) between the prevalence
130 II, 5. 9. 3 | remarkable in German children (p <0,05)~ ~The survey by Compalati
131 II, 5. 9. 4 | for wheeze (1.34 to 0.98:1 P <0.0002), asthma (1.74 to
132 II, 5. 9. 4 | asthma (1.74 to 1.02:1 P <0.0001), eczema (1.42:1
133 II, 5. 9. 4 | eczema (1.42:1 to 0.81:1 P <0.0001) and hay fever (
134 II, 5. 9. 4 | hay fever (1.46 to 0.93:1 P <0.0001). The diagnosis
135 II, 5. 9. 4 | risk=1.6, 95% CI 1.1-2.3, P=0.017). Risks were higher
136 II, 5. 9. 4 | symptoms (2.4, 1.3-4.6, P=0.008). Among common occupations,
137 II, 5. 9. 4 | for nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was
138 II, 5. 9. 4 | RR=3.3, 95% CI 1.0-11.1, P=0.051). The population-attributable
139 II, 5. 9. 4 | levels of the epitope Dep p 1 of house dust mites (MAS
140 II, 5. 9. 4 | sensitization to Olea europea and P. judaica is higher in Southern
141 II, 5. 9. 4 | and 8.0% of the females (P=0.03). Analysis by multiple
142 II, 5. 9. 4 | the time spent in Apulia (P=0.04 for hay-fever) (Ventura
143 II, 5. 9. 4 | and 9.7% respectively, P <0.001; current wheeze:
144 II, 5. 9. 4 | and 6.9%, respectively, P = 0.04). Lower risks for
145 II, 5. 9. 7 | Kogevinas M, Jarvis D, Burney P. (2007a): Nu I. Clin Exp
146 II, 5. 9. 7 | Janson C, Kogevinas M, Burney P, Jarvis D (2007b): Ge I.
147 II, 5. 10. 7 | Pumphrey RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra
148 II, 5. 10. 7 | Anklam E, Baumgartner S, Koch P, Crevel RW, Frewer L (2004):
149 II, 5. 10. 7 | Mills ENC, Mackie AR, Burney P, Beyer K, Frewer L, Madsen
150 II, 5. 11. 7 | Venereol 2001;81:193-7.~ ~Boyle P, Dorè JF, Autier P, Ringborg
151 II, 5. 11. 7 | Boyle P, Dorè JF, Autier P, Ringborg U (2004): Cancer
152 II, 5. 11. 7 | 2004;15(1):5-6.~ ~Boyle P, Smans M (2003): Cancer
153 II, 5. 11. 7 | Ferlay J, Bray F, Pisani P, Parkin DM (2001): GLOBOCAN
154 II, 5. 11. 7 | G, Obsitnikova A, Boyle P. Trends in the incidence
155 II, 5. 11. 7 | 151(2):446-51.~ ~Verboom P, Hakkaart-van Roijen L,
156 II, 5. 11. 7 | L, Coenraads PJ, Elsner P, Grob JJ, Bouwes Bavick
157 II, 5. 12. 7 | 169.~ ~Corrao G, Ferrari P, Zambon A, Torchio P, Arico
158 II, 5. 12. 7 | Ferrari P, Zambon A, Torchio P, Arico S, Decarli A (1997):
159 II, 5. 12. 7 | 27:914-919.~ ~D'Argenio P, Esposito D, Mele A, Ortolani
160 II, 5. 12. 7 | Adamo B, Rapicetta M, Forte P,~Pisani A, Soldo L, Sarrecchia
161 II, 5. 12. 7 | Suppl 1:S19-33.~ ~Sauer P, Hansmann J, Richter GM,
162 II, 5. 15. 6 | Dear JW, Lilitkarntakul P, Webb DJ (2006): Are rare diseases
163 II, 5. 15. 6 | Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J (2007):
164 II, 5. 15. 6 | Wilson DA, Kanavos P, Ubel P, Rovira J (2007): Assessing
165 II, 8. 2. 1 | Disabilities 18, 295-304.~Kramers, P.G.N., (2003). The ECHI project:
166 II, 8. 2. 1 | Limited.~Linehan, C., Walsh, P.N., et al., (2007). POMONA
167 II, 8. 2. 1 | H., Simpson, N., Patel, P., & Rowe, S. (1998). Reliability
168 II, 8. 2. 1 | eurpub/13.suppl_1.47~Walsh, P.N., Linehan, C., Kerr, M.,
169 II, 9 | Pomerleau et al, 2003: p. 455~ ~Levels of physical activity
170 II, 9. 1. 1 | Oury JF, Luton D, Blot P (2002): Differences in management
171 II, 9. 1. 1 | S45-52.~ ~Cans C, Guillem P, Fauconnier J, Rambaud P,
172 II, 9. 1. 1 | P, Fauconnier J, Rambaud P, Jouk PS (2003): Disabilities
173 II, 9. 1. 1 | Glinianaia SV, Pharoah P, Sturgiss SN (2000): Comparative
174 II, 9. 1. 1 | Cnattingius S, Bergsjo P (2002): Registration artifacts
175 II, 9. 1. 1 | Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan D,
176 II, 9. 1. 2 | Stoll C and Mastroiacovo P (2006): "Trends of Selected
177 II, 9. 1. 2 | Gatt M, de Walle H, Braz P, Latos-Bielenska A, Gener
178 II, 9. 1. 2 | Genetics 2007; 10:93-6.~De Wals P et al, (2007): Reduction
179 II, 9. 1. 2 | C, Garbis H, McElhatton P, Reuvers M, Robert E, Rost
180 II, 9. 1. 2 | Tonningen M, Scialli A, Peters P (2001): Drugs during pregnancy
181 II, 9. 2. 7 | Eurobarometer Issue No. 246 p 13. 9 November, 2006~ ~European
182 II, 9. 2. 7 | accessed 11.06)~ ~Heuveline P., Timberlake J.M. (2000):
183 II, 9. 3. 1 | distribution” (WHO, 2000, p.6), and with the recognition
184 II, 9. 3. 1 | are at ‘specific risk’ (p.35) there are few initiatives
185 II, 9. 3. 1 | Pomerleau et al, 2003: p. 455~ ~Levels of physical activity
186 II, 9. 3. 1 | Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J (2007):
187 II, 9. 3. 1 | Sen. George GA and Östlin P). MITPress, Cambridge~ ~
188 II, 9. 3. 1 | Journal of Urology. 84(1): p. 50-56.~ ~Beral V (2003):
189 II, 9. 3. 1 | 9382; 419-427.~ ~Boyle, P. Robertson, C. Mazzeha,
190 II, 9. 3. 1 | 92. 943 – 947~ ~Branney, P White, AK (2008) Big boys
191 II, 9. 3. 1 | Impotence Research. 12(6): p. 305-311.~ ~British Heart
192 II, 9. 3. 1 | Journal of Psychiatry, 39: p. 921 - 931.~ ~De Smedt M (
193 II, 9. 3. 1 | veille sanitaire, No. 72. p 6~ ~European Agency for
194 II, 9. 3. 1 | pp. 245-253(9)~ ~Gabriel P, Liimatainen M-R (2000):
195 II, 9. 3. 1 | Cancer Inst, 1997. 89(20): p. 1516-23~ ~Makino M, Tsuboi
196 II, 9. 3. 1 | Qaseem, A Snow, V Shekelle, P Hopkins Jr R. Forciea, MA
197 II, 9. 3. 1 | Journal of Urology. 90: p. 433-441.~ ~UNAIDS, UNFPA,
198 II, 9. 3. 2 | Oury JF, Luton D, Blot P (2002): Differences in management
199 II, 9. 3. 2 | S45-52.~ ~Cans C, Guillem P, Fauconnier J, Rambaud P,
200 II, 9. 3. 2 | P, Fauconnier J, Rambaud P, Jouk PS (2003): Disabilities
201 II, 9. 3. 2 | Glinianaia SV, Pharoah P, Sturgiss SN (2000): Comparative
202 II, 9. 3. 2 | Cnattingius S, Bergsjo P (2002): Registration artifacts
203 II, 9. 3. 2 | J, Dekker G, van Dongen P, van Geijn H, Bennebroek
204 II, 9. 3. 2 | 1998;79(1):57-62.~ ~Semenow P (1872) : Compte-rendu général
205 II, 9. 3. 2 | M, Foster LB, Hannaford P, Cattaneo A, Olsen J, Bloemenkamp
206 II, 9. 3. 2 | Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan D,
207 II, 9. 3. 3 | Bochow M, Chiarotti F, davies P, Dubois-Arber F, Dür W,
208 II, 9. 3. 3 | Journal C 271 E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires
209 II, 9. 3. 3 | their parents. BZgA, 124 p. htt de~Hubert M, Bajos
210 II, 9. 3. 3 | UCL Press. London. 442 p.~Imamura M, Tucker J, Hannaford
211 II, 9. 3. 3 | Imamura M, Tucker J, Hannaford P, da Silva MO, Astin M, Wyness
212 II, 9. 3. 3 | Health and Children. 62 p. [http://www.crisispregnancy.
213 II, 9. 3. 3 | 1141-42.~Nikula M, Kaponen P, Haavio-Mannila E, Hemminki
214 II, 9. 3. 3 | Prev Med 41:247-52.~Weiss,P.(2008) Trends and risk factors
215 II, 9. 3. 3 | Available at: htt df~Wilkinson P, French R, Kane R, et al (
216 II, 9. 4. 7 | Biol Sci Med Sci, (12), p.1277-84.~DECODE study group
217 II, 9. 4. 7 | 10/2006~ ~Gray A, Fenn P, (1993): Alzheimer’s disease:
218 II, 9. 4. 7 | Europe.~ ~Jaleel H, Allan P S, Wade A A (1999): Sexually
219 II, 9. 4. 7 | Health, Volume 13, No. 2 p. 56-61. March 2005~ ~United
220 II, 9. 5. 6 | George Sen. G.A, Östlin P). MITPress, Cambridge.~ ~
221 II, 9. 5. 6 | 245~ ~Brodin J, Lindstrand P (2006): Research Report
222 II, 9. 5. 6 | Perspective.. (Edited by Östlin P, Danielsson M, Diderichsen
223 II, 9. 5. 6 | Health, Volume 13, No. 2 p. 56-61. March 2005~ ~Wang
224 II, 9. 5. 6 | of Public Health, 4th ed, p 1596~ ~White AK, Holmes
225 III, 10. 1. 3 | Oxford University Press; p. 83-87.~Blow FC, Brockmann
226 III, 10. 1. 3 | Oxford University Press; p. 113-130.~Hart N (2004):
227 III, 10. 1. 3 | Oxford University Press; p. 89-111.~Jacobs J, Wolin
228 III, 10. 1. 3 | and Barlett Publishers; p. 205-8.~Tappy L, Binnert
229 III, 10. 2. 1 | Control; 12:360-367~ ~Boyle P, Autier P, Bartelink H,
230 III, 10. 2. 1 | 360-367~ ~Boyle P, Autier P, Bartelink H, Baselga J,
231 III, 10. 2. 1 | Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJG, Christensen
232 III, 10. 2. 1 | F, McVie JC, Maisonneuve P, Martin-Moreno JM, Newton
233 III, 10. 2. 1 | Bishop J, Oleari F, Perrin P, Quinn M, Richards M, Ringborg
234 III, 10. 2. 1 | C, Neukirch F, Vermeire P, Wjst M and Burney P (2006):
235 III, 10. 2. 1 | Vermeire P, Wjst M and Burney P (2006): Changes in active
236 III, 10. 2. 1 | Adami J, Adami H-O, Bofetta P, Nyrén O (2007): Oral use
237 III, 10. 2. 1 | 5. References~ ~Anderson P, Baumberg B (2006): Alcohol
238 III, 10. 2. 1 | Available at:~htt ~ ~Anderson P, (2007): Commercial Communications
239 III, 10. 2. 1 | Blomgren J, Martikainen P, Mäkelä P, Valkonen T, (
240 III, 10. 2. 1 | J, Martikainen P, Mäkelä P, Valkonen T, (2004): "The
241 III, 10. 2. 1 | 99.~ ~Miller W, Wilbourne P (2002): Mesa Grande: a methodological
242 III, 10. 2. 1 | C, Lagerlof F, Lingstrom P, Mejare I, Norderam G, Norlund
243 III, 10. 2. 1 | physical activity. In: Oja P, Borms J., eds. Health-enhancing
244 III, 10. 2. 1 | 116:7-13.~ ~Gordon-Larsen P et al. (2006): Inequality
245 III, 10. 2. 1 | Central Books.~ ~Hassmen P, Koivula N, Uutela A (2000):
246 III, 10. 2. 1 | Duffey K, Gordon-Larsen P (2005): Environmental influences
247 III, 10. 2. 1 | Health Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~Data
248 III, 10. 2. 1 | OJ C 250 E, 25.10.2007, p. 93~· White Paper on “A
249 III, 10. 2. 1 | Journal L 052 , 22/02/2001 P. 0019 – 0025.~http://eur-lex.
250 III, 10. 2. 1 | Journal L 083 , 22/03/2006 P. 0014 – 0015.~[http://eur-lex.
251 III, 10. 2. 1 | Journal L 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.
252 III, 10. 2. 1 | Journal L 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex.
253 III, 10. 2. 1 | Journal L 404 , 30/12/2006 P. 0009 – 0025 [http://eur-lex.
254 III, 10. 2. 1 | Journal L 404 , 30/12/2006 P. 0026 – 0038.~[http://eur-lex.
255 III, 10. 2. 1 | 362.~ ~Gallus S, Colombo P, Scarpino V, Zuccaro P,
256 III, 10. 2. 1 | Colombo P, Scarpino V, Zuccaro P, Negri E, Apolone G, La
257 III, 10. 2. 1 | World Health Organization; p. 497–596.~[ht ] (report
258 III, 10. 2. 1 | Fernandes T, Mourão I, Moreira P, Rosado V (2004): Prevalence
259 III, 10. 2. 1 | Rodrigo C, Saavedra Santana P, Peña Quintana L (2003):
260 III, 10. 2. 1 | Stamatakis E, Primatesta P, Chinn S, Rona R, Falascheti
261 III, 10. 2. 1 | Warsaw, Prace IŻŻ 101; p. 444-508 (in Polish).~ ~
262 III, 10. 2. 1 | Tedstone A, Aviles M, Shetty P, Daniels L (1998): Effectiveness
263 III, 10. 2. 1 | 2000~ ~Hercberg S, Preziosi P, Galan P (2001): Iron deficiency
264 III, 10. 2. 1 | Hercberg S, Preziosi P, Galan P (2001): Iron deficiency
265 III, 10. 2. 1 | Bamia C, Karalis D, Vineis P, Palli D, Bueno-de-Mesquita
266 III, 10. 2. 1 | Martinez GC, Wallstrom P, Zhang JX, Welch AA, Spencer
267 III, 10. 2. 1 | Skeie G, Aller A, Amiano P, Berglund G, Nilsson S,
268 III, 10. 2. 1 | Haftenberger M, Lagiou P, Kalapothaki V, Evangelista
269 III, 10. 2. 1 | Dorronsoro Iraeta M, Morote Gomez P, Janzon L, Stattin P, Welch
270 III, 10. 2. 1 | Gomez P, Janzon L, Stattin P, Welch AA, Spencer EA, Overvad
271 III, 10. 2. 1 | Klipstein-Grobusch K, Lagiou P, Kalapothaki V, Masala G,
272 III, 10. 2. 1 | Dorronsoro Iraeta M, Morote Gomez P, Chirlaque MD, Pozo BG,
273 III, 10. 2. 1 | Welch AA, Lund E, Amiano P, Dorronsoro M, Brustad M,
274 III, 10. 2. 4 | 116.~ ~Brand A, Schröder P, Brand H, Zimmern R (2006):
275 III, 10. 2. 4 | Mattheisen M, Dahm S, Nürnberg P, Roe C, Johnson J, Cox N
276 III, 10. 2. 4 | T F, Schulze J, Schwarz P E, Lindner T H (2007): A
277 III, 10. 2. 4 | Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J,
278 III, 10. 2. 4 | Roberts, R, Sullivan P, Joyce P, Kennedy M (2000):,
279 III, 10. 2. 4 | Roberts, R, Sullivan P, Joyce P, Kennedy M (2000):, Rapid
280 III, 10. 2. 4 | Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson
281 III, 10. 2. 4 | Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder
282 III, 10. 2. 4 | Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly
283 III, 10. 2. 4 | Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet
284 III, 10. 2. 4 | Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross
285 III, 10. 2. 5 | Brubakk AM, Romundstad P, Vik T (2007): Prenatal
286 III, 10. 3. 2 | in DDT and its metabolite p,p’-DDE, and lesser decreases
287 III, 10. 3. 2 | DDT and its metabolite p,p’-DDE, and lesser decreases
288 III, 10. 3. 2 | Grandjean PJ, Landrigan P (2006): Developmental neurotoxicity
289 III, 10. 3. 2 | Alimonti, F Petrucci, B Bocca, P Schramel, M Zischka, C Pettersson,
290 III, 10. 4. 1 | Hurley, F., Pye S., Watkiss P. and Hunt A. (2007) improving
291 III, 10. 4. 2(28)| EEC (OJ L 187, 16.7.2002, p 30)~
292 III, 10. 4. 2(29)| EEC(OJ L 325,12.12.2003 p. 31)~
293 III, 10. 4. 2(30)| OJ 121, 29.7.1964, p.1977~
294 III, 10. 4. 2(31)| OJ L 224, 18.8.1990, p.19~
295 III, 10. 4. 2(32)| OJ 186, 30.6.1989, p.23~
296 III, 10. 4. 2(33)| Community (OJ L 268, 3.10.1998,p.1)~
297 III, 10. 4. 2(35)| cereals (OJ L 221, 7.8.1986, p 37).~
298 III, 10. 4. 2(36)| origin (OJ L 221, 7.8.1986, p 43).~
299 III, 10. 4. 2(37)| vegetables (OJ L 350,14.12.1986, p 71).~
300 III, 10. 5. 1 | Vandentorren et al, 2007; Wilkinson P. et al, 2007). Such extreme
301 III, 10. 5. 1 | Cities. Vol. 23. Issue 5. P. 339–352.~Bayerisches Landesamt
302 III, 10. 5. 1 | Washington: Feb 2003, vol 93, p 288~Said B et al. Outbreaks
303 III, 10. 5. 1 | Viegi G, Canciani M, Sestini P (2006): La qualità dell’
304 III, 10. 5. 1 | 6, 583–591;~ ~Wargocki P, Wyon DP (2007): The effects
305 III, 10. 5. 1 | Available at: htt ~ ~Wilkinson P, et al (2007): Energy, energy
306 III, 10. 5. 3 | 296-320.~Andlin-Sobocki P, Jönsson B, Wittchen H-U,
307 III, 10. 5. 3 | 1610-1619.~Martikainen, P. & Valkonen, T. (1996).
308 III, 10. 5. 3 | Democracy. New York, Harper; p. 82-85.~Thomas T, Secker
309 III, 10. 6. 1 | Brand RJ, Syme SL, Puska P (1988). Social connections
310 IV, 11. 6. 5 | Health 12(2): 7-9.~ ~Belli P (2003): Formal and informal
311 IV, 11. 6. 5 | Health Care. 2002; 18(2), p 364.~ ~Carrin G, Hanvoravongchai
312 IV, 11. 6. 5 | Carrin G, Hanvoravongchai P (2003): "Provider payments
313 IV, 11. 6. 5 | Physician 67(4): 697.~ ~Durieux P, Chaix-Couturier C et al. (
314 IV, 11. 6. 5 | Hall.~ ~Goddard M, Smith P (2001): "Equity of access
315 IV, 11. 6. 5 | Health Economics.~ ~Kanavos P, Mossialos E (1999): "International
316 IV, 11. 6. 5 | and Policies.~ ~Musgrove P (2003): "Judging health
317 IV, 11. 6. 5 | performance in OECD countries. P. Smith. Paris, Organisation
318 IV, 11. 6. 5 | 55-72.~ ~Rice N, Smith P (2002): Strategic resource
319 IV, 11. 6. 5 | and development.~ ~Smith P, Ed. (2002): Measuring Up:
320 IV, 11. 6. 5 | and Development.~ ~Smith P (2004): "Health care reforms
321 IV, 11. 6. 5 | 95.~ ~Sorenson C, Kanavos P et al. (2007): Ensuring
322 IV, 11. 6. 5 | Approaches for New Outcomes. P. Cox.~ ~Spooner A, Chapple
323 IV, 11. 6. 5 | 2nd ed., 1998~ ~Vaughan, J.P., Morrow, R.H. Manual of
324 IV, 12. 1 | Freedom,~Security Justice Data P rotecti on~ ~ ~Protection
325 IV, 13. 9 | References~ ~Andlin-Sobocki P, Jönsson B, Wittchen HU,
|
|
| |
